CytoSorbents Corporation, a critical care company that specialises in blood purification to treat life-threatening conditions has announced the registration of a new subsidiary, CytoSorbents Medical UK Limited. The company plans to expand the use of its flagship product, CytoSorb, in hospitals throughout the UK and Ireland.
Shaun Whittemore, Country Manager, UK & Ireland has recently been hired by the company to drive and coordinate market development in the region, and said: “I am delighted to be part of this exciting opportunity to further develop and grow the market for CytoSorb in the United Kingdom and the Republic of Ireland and expect to leverage my insight and expertise from a career extending over two decades within the healthcare sector. I believe the benefits of our innovative blood purification technology will make a positive impact on the lives of treated patients throughout the region.”
CytoSorb, which was previously sold via distributor partners in the UK and Ireland, is an extracorporeal cytokine adsorber designed to reduce the sometimes deadly inflammation found in critically-ill patients in the intensive care unit. The device has been used for patients suffering from many diseases and viruses, including COVID-19, sepsis, trauma, burn injuries, liver failure, as well patients undergoing procedures such as complex open-heart surgery.
Dr Christian Steiner, Executive Vice President, Sales and Marketing of CytoSorbents, added: “As we establish a direct sales team in the UK and Ireland, we are excited to work more closely with physicians to improve awareness and usage of CytoSorb in its many applications in critical care and cardiac surgery."
"We also expect to continue working with the UK’s National Health Service (NHS), one of the world’s largest and well-renowned healthcare systems, to educate them on the clinical benefits and cost-effectiveness of our technology. To begin with, we plan to highlight last year’s NICE Medtech innovation briefing on the use of CytoSorb to reduce the risk of bleeding during cardiothoracic surgery in patients on blood-thinning medications in the UK health system."